Unveiling Bisabolol’s Promise: A Molecular Docking Insight into Its Therapeutic Potential for Neurological Disorders

Neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and epilepsy are often associated with oxidative stress, neuroinflammation, and synaptic dysfunction. Bisabolol, a monocyclic sesquiterpene alcohol abundant in chamomile, has been documented to exhibit potent anti-inflammatory, antioxidant, and neuroprotective activities. In this study, we explore the potential of bisabolol as a therapeutic agent for neurological disorders through a molecular docking approach. The interaction between bisabolol and key molecular targets involved in neuroinflammation and oxidative stress, such as γ-aminobutyric acid type receptors, Muscarinic acetyl choline receptors, D2 dopamine receptor, N-methyl-D-aspartate receptors etc., was assessed to determine the binding affinity and possible mechanism of action. The docking results reveal moderate to strong binding affinity of bisabolol with these targets, supporting its potential role in mitigating neurodegeneration and synaptic damage. Further in vitro and in vivo studies are warranted to confirm the therapeutic efficacy of bisabolol in treating neurological disorders.